StemCyte is a global cell therapy company. In past decades, we collaborate with 350 medical centers during the world and rescue more than 2,300 patients by using our cord blood units. Meanwhile, we focus on cord blood cell applications in different disease treatment including spinal cord injury, acute stroke, cerebral palsy and cancer. Based on our cord blood bank resource, we are devoting to develop the cord blood derived NK cell technology for clinical use. Our advanced cell product, SCTcb-201 (Allogenic CB-NK), is the first cord blood derived NK cells in Taiwan and also a competitive cell product in the world.